The evaluation of trebananib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL

被引：3

作者：

Albain, K. S.

Leyland-Jones, B.

Symmans, F.

Paoloni, M.

van't Veer, L.

DeMichele, A.

Buxton, M.

Hylton, N.

Yee, D.

Clennell, J. Lyandres

Yau, C.

Sanil, A.

Berry, D.

Esserman, L.

机构：

[1] Loyola Univ, Chicago Stritch Sch Med, New Orleans, LA 70118 USA

[2] Avera Med Grp, Worthington, MN USA

[3] Univ Texas MD Anderson Canc Ctr, Bethesda, MD USA

[4] QuantumLeap Healthcare Collaborat, San Francisco, CA USA

[5] Univ Calif San Francisco, San Francisco, CA 94143 USA

[6] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[7] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA

[8] Berry Consultants, Austin, TX USA

来源：

CANCER RESEARCH | 2016年 / 76卷

关键词：

D O I：

10.1158/1538-7445.SABCS15-P1-14-03

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1-14-03

引用

页数：1

共 50 条

[1] Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Park, John W.
Liu, Minetta C.
Yee, Douglas
DeMichele, Angela
van't Veer, Laura
Hylton, Nola
Symmans, Fraser
Buxton, Meredith B.
Chien, A. Jo
Wallace, Amy
Melisko, Michelle
Schwab, Richard
Boughey, Judy
Tripathy, Debashish
Kaplan, Hank
Nanda, Rita
Chui, Stephen
Albain, Kathy S.
Moulder, Stacy
Elias, Anthony
Lang, Julie E.
Edminston, Kirsten
Northfelt, Donald
Euhus, David
Khan, Qamar
Lyandres, Julia
Davis, Sarah E.
Yau, Christina
Sanil, Ashish
Esserman, Laura J.
Berry, Donald A.
[J]. CANCER RESEARCH, 2014, 74 (19)
[2] Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): Results from I-SPY 2
Nanda, Rita
Liu, Minetta C.
Yau, Christina
Asare, Smita
Hylton, Nola
Van't Veer, Laura
Perlmutter, Jane
Wallace, Anne M.
Chien, Amy Jo
Forero-Torres, Andres
Ellis, Erin
Han, Heather
Clark, Amy Sanders
Albain, Kathy S.
Boughey, Judy Caroline
Elias, Anthony D.
Berry, Donald A.
Yee, Douglas
DeMichele, Angela
Esserman, Laura
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[3] Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIAL
Rugo, H. S.
Olopade, O.
DeMichele, A.
van't Veer, L.
Buxton, M.
Hylton, N.
Yee, D.
Chien, A. J.
Wallace, A.
Lyandres, J.
Davis, S.
Sanil, A.
Berry, D.
Esserman, L.
[J]. CANCER RESEARCH, 2013, 73
[4] Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial
Glas, A.
Peeters, J.
Yau, C.
Wolf, D. M.
Sanil, A.
Li, Y.
Severson, T.
Linn, S.
Buxton, M.
DeMichele, A.
Hylton, N.
Symmans, F.
Yee, D.
Paoloni, M.
Esserman, L.
Berry, D.
Rugo, H.
Olopade, O.
van 't Veer, L. J.
[J]. EUROPEAN JOURNAL OF CANCER, 2014, 50 : 173 - 173
[5] Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu, Minetta C.
Robinson, Patricia A.
Yau, Christina
Wallace, Anne M.
Chien, A. Jo
Stringer-Reasor, Erica
Nanda, Rita
Yee, Douglas
Albain, Kathy S.
Boughey, Judy C.
Han, Heather S.
Elias, Anthony D.
Kalinsky, Kevin
Clark, Amy S.
Kemmer, Kathleen
Isaacs, Claudine
Lang, Julie E.
Lu, Janice
Sanft, Tara
DeMichele, Angela
Hylton, Nola M.
Melisko, Michelle E.
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Symmans, W. Fraser
van't Veer, Laura J.
Haugen, Patricia K.
Wilson, Amy
Singhrao, Ruby
Asare, Smita
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)
[6] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Wang, Haiyun
Yee, Douglas
[J]. CURRENT BREAST CANCER REPORTS, 2019, 11 (04) : 303 - 310
[7] I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer
Haiyun Wang
Douglas Yee
[J]. Current Breast Cancer Reports, 2019, 11 : 303 - 310
[8] Evaluation of an in vitro derived signature of olaparib response (PARPi-7) as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 TRIAL
Wolf, Denise M.
Yau, Christina
Sanil, Ashish
Daemen, Anneleen
Heiser, Laura
Gray, Joe
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian
Buxton, Meredith
DeMichele, Angela
Hylton, Nola
Symmans, Fraser
Yee, Doug
Paoloni, Melissa
Esserman, Laura
Berry, Don
Rugo, Hope
Olopade, Olufunmilayo
van't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[9] MammaPrint High1/High2 risk class as a biomarker of response to neratinib plus standard neoadjuvant therapy for breast cancer in the I-SPY 2 TRIAL
Yau, Christina
Wolf, Denise M.
Sanil, Ashish
Chien, Jo
Wallace, Anne
Boughey, Judy
Yee, Doug
Tripathy, Debu
DeMichele, Angela
Nanda, Rita
Chiu, Steven
Isaacs, Claudine
Albain, Kathy
Kaplan, Hank
Moulder, Stacey
Viscusi, Rebecca
Northfelt, Donald
Edmiston, Kirsten
Elias, Anthony
Styblo, Toncred
Haley, Barbara
Brown-Swigart, Lamorna
Flynn, Susan
Hirst, Gillian L.
Buxton, Meredith
Hylton, Nola
Paoloni, Melissa
Symmans, W. Fraser
Esserman, Laura
Berry, Don
Liu, Minetta C.
Park, John W.
van 't Veer, Laura
[J]. CANCER RESEARCH, 2015, 75
[10] Evaluation of patritumab/paclitaxel/trastuzumab over standard paclitaxel/trastuzumab in early stage, high-risk HER2 positive breast cancer: Results from the neoadjuvant I-SPY 2 trial
Helsten, Teresa L.
Lo, Shelly S.
Yau, Christina
Kalinsky, Kevin
Elias, Anthony D.
Wallace, Anne M.
Chien, A. Jo
Lu, Janice
Lang, Julie E.
Albain, Kathy S.
Stringer-Reasor, Erica
Clark, Amy S.
Boughey, Judy C.
Ellis, Erin D.
Yee, Douglas
DeMichele, Angela
Isaacs, Claudine
Perlmutter, Jane
Rugo, Hope S.
Schwab, Richard
Hylton, Nola M.
Symmans, W. Fraser
Melisko, Michelle E.
van't Veer, Laura J.
Wilson, Amy
Singhrao, Ruby
Asare, Smita M.
Sanil, Ashish
Berry, Donald A.
Esserman, Laura J.
[J]. CANCER RESEARCH, 2020, 80 (04)

← 1 2 3 4 5 →